

# Jupiter Neurosciences Selected as B2i Digital Featured Company

*Clinical-Stage Pharmaceutical Company  
Advancing Phase IIa Parkinson's Trial*

NEW YORK, NY, UNITED STATES,  
February 13, 2026 /EINPresswire.com/  
-- B2i Digital, Inc., a capital markets  
positioning and investor connectivity  
platform focused on growth-stage  
public companies, today announced  
that [Jupiter Neurosciences, Inc.](#)  
(NASDAQ: JUNS) has been selected as a  
[B2i Digital Featured Company](#).

Jupiter Neurosciences is advancing a  
therapeutic pipeline targeting  
neuroinflammation and central  
nervous system (CNS) disorders, led by  
an FDA-cleared Phase IIa clinical trial in  
Parkinson's disease. The company is  
also exploring additional indications,  
including Alzheimer's disease,  
Friedreich's Ataxia,  
Mucopolysaccharidoses Type I, and  
MELAS, supported by research  
collaborations with Harvard University,  
Georgetown University, MIT's Picower  
Institute, and the University of Miami.

Alongside its clinical program, Jupiter is  
expanding a consumer brand powered  
by its proprietary JOTROL™ enhanced  
resveratrol formulation. This dual-path strategy combines clinical development with emerging  
commercial revenue pathways, creating a differentiated operating model as key milestones  
advance.

"Jupiter Neurosciences offers investors a differentiated opportunity within the CNS sector," said



Dual-Path Strategy Targets Neuroinflammation While  
Expanding its consumer product line



Alongside its clinical program, Jupiter is expanding a  
consumer brand powered by its proprietary JOTROL™  
enhanced resveratrol formulation.



With a Phase IIa Parkinson's trial underway and a consumer product platform already in market, the company is advancing its pipeline while building potential revenue streams."

*David Shapiro, CEO of B2i Digital, Inc.*

David Shapiro, Chief Executive Officer of B2i Digital. "With a Phase IIa Parkinson's trial underway and a consumer platform already in market, the company is advancing its pipeline while building potential revenue streams. We look forward to expanding their visibility across our investor network."

"We believe we are entering an important inflection point," said Christer Rosén, Founder, Chairman, and CEO of Jupiter Neurosciences. "As our Parkinson's program progresses and our consumer products continue to scale, partnering with B2i Digital strengthens our ability to

communicate our story to the broader capital markets."

To learn more about Jupiter Neurosciences, visit [www.jupiterneurosciences.com](http://www.jupiterneurosciences.com). For investor inquiries, contact [IR@jupiterneurosciences.com](mailto:IR@jupiterneurosciences.com).

#### [About B2i Digital, Inc.](#)

B2i Digital, Inc. is a capital-markets positioning and investor-connection platform serving growth-stage public companies. Through its Featured Conference, Featured Company, and Featured Expert programs, B2i Digital helps management teams sharpen their capital markets narrative and engage directly with active investors across the investor conference ecosystem.

Acting as The Capital Markets Matchmaker<sup>SM</sup>, B2i Digital leverages a proprietary network of more than 1.5 million capital markets participants and a curated email distribution of more than 100,000 investors and industry professionals to move companies from marketing to meaningful investor meetings. Its approach, captured in the mantra From Marketing to Meetings<sup>SM</sup>, reflects a focus on measurable investor engagement. Founded in 2021 by former Maxim Group investment banker and Chief Marketing Officer David Shapiro, B2i Digital is headquartered in New York City.

#### B2i Digital Contact Information:

David Shapiro

Chief Executive Officer

B2i Digital, Inc.

<https://b2idigital.com>

212.579.4844 Office

[david@b2idigital.com](mailto:david@b2idigital.com)

<https://www.linkedin.com/in/davidshapironyc>

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases while expanding its consumer product line. Both initiatives are powered by JOTROL™, Jupiter's proprietary enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Our consumer products leverage clinical-grade science in supporting mental clarity, skin health, and mitochondrial function. The Company's pipeline is focused broadly on CNS disorders and currently includes a Phase IIa clinical trial in Parkinson's disease, with additional exploration in Alzheimer's disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

More information is available at [www.jupiterneurosciences.com](http://www.jupiterneurosciences.com).

#### Contact Information:

Jupiter Neurosciences, Inc.

IR@jupiterneurosciences.com

<https://www.linkedin.com/company/jupiterneurosciences/>

<https://x.com/jupiterneuro>

#### Media:

David Shapiro

B2i Digital, Inc.

+1 212-579-4844

david@b2idigital.com

Visit us on social media:

[LinkedIn](#)

[Bluesky](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[TikTok](#)

[X](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/891825901>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

